Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02584855 · ClinicalTrials.gov registry record · Phase 3
A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Phase 3 study of Psoriatic Arthritis, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 394
- Enrollment target
- 20
- Study locations
NCT02584855 is a Phase 3 study of Psoriatic Arthritis that has completed, run by Eli Lilly and Company. The registered enrollment target is 394 participants, below the 845-participant average among 48 other Psoriatic Arthritis trials with a reported enrollment target (53% lower). The trial reports 20 study locations across 14 states.
The verdict
NCT02584855, a Phase 3 study of Psoriatic Arthritis, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 394 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main purpose of this study is to evaluate the safety and long-term efficacy of ixekizumab compared to placebo in participants with active psoriatic arthritis.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Ixekizumab
Study Locations (20)
Arizona
- Arizona Arthritis & Rheumatology Research - Glendale
- Arizona Arthritis & Rheumatology Research, PLLC - Mesa
- Arizona Arthritis Research, PLC - Phoenix
California
- University of California, Davis - Health Systems - Sacramento
- East Bay Rheumatology Medical Group - San Leandro
Florida
- Arthritis & Osteoporosis Treatment Center, PA - Orange Park
- Florida Medical Clinic PA - Zephyrhills
Maryland
- Klein and Associates MD, PA - Cumberland
- Klein and Associates MD, PA - Hagerstown
Texas
- Pioneer Research Solutions - Cypress
- Arthritis Care & Diagnostic Center P.A. - Dallas
Iowa
- Physicians Clinic of Iowa - Cedar Rapids
Kansas
- Heartland Research Associates - Wichita
Massachusetts
- University of Massachusetts Medical Center - Worcester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 394 participants |
| Start Date | 2015-09-14 |
| Est. Completion | 2018-10-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02584855
The ClinicalTrials.gov registry entry for NCT02584855 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 394 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 845-participant average among 48 other Psoriatic Arthritis trials with a reported enrollment target (53% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Psoriatic Arthritis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02584855 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Arizona, California, Florida.
Frequently Asked Questions
What is clinical trial NCT02584855 about?
NCT02584855 is a clinical study titled "A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis". The main purpose of this study is to evaluate the safety and long-term efficacy of ixekizumab compared to placebo in participants with active psoriatic arthritis.
What is the current status of trial NCT02584855?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 394 participants. The study started on 2015-09-14. Estimated completion is 2018-10-30.
What conditions does trial NCT02584855 study?
This clinical trial studies the following conditions: Psoriatic Arthritis.
What interventions are being tested in trial NCT02584855?
The interventions under investigation include: Placebo (DRUG), Ixekizumab (DRUG).
Who is sponsoring clinical trial NCT02584855?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02584855 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Iowa, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psoriatic Arthritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis
RECRUITING · Phase 3
-
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines
RECRUITING · Phase 3
-
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines
RECRUITING · Phase 3
-
A Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis
RECRUITING · Phase 3
-
Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients
RECRUITING · Phase 3
-
Long Term Evaluation of Safety and Efficacy of Tildrakizumab in Patients With Psoriatic Arthritis
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.